Which binge eating disorder drugs are in Phase 3?

Phase 3 (or later) programs for binge eating disorder include Solriamfetol (Sunosi).

What are the next binge eating disorder trial readouts?

Upcoming catalysts include Solriamfetol (Sunosi) (2H 2026).

5 drug-interventional binge eating disorder trials are currently recruiting participants, out of 62 registered interventional trials.

1 compound from 1 company is in active clinical development for binge eating disorder, including 1 at Phase 3 or beyond.

1Compound

1Company

1Phase 3+

1Upcoming readout

6Trials recruiting

Mechanisms: Small molecule (1)

Pipeline data compiled July 2026 · every fact sourced.

2H 2026AnticipatedSolriamfetol (Sunosi)Topline datapendingNCT06413433
ENGAGE Phase 3 (solriamfetol in binge eating disorder) topline results anticipated in the second half of 2026. ↗

Compound	Company	Phase	Status	Mechanism
Solriamfetol (Sunosi)	Axsome Therapeutics, Inc.	Phase 3	Recruiting	NET Reuptake inhibitor

5 drug-interventional binge eating disorder trials recruiting now, of 62 registered interventional trials. Browse all on ClinicalTrials.gov →

Phase 3An Open-Label Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Adults With Binge Eating Disorder
Solriamfetol 75mg, 150 mg, or 300 mg
Axsome Therapeutics, Inc.n=300United States · 31 sitesStarted Feb 2025Tracked: Solriamfetol (Sunosi)NCT06878976
Phase 3A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED) (ENGAGE)
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Axsome Therapeutics, Inc.n=450United States · 45 sitesStarted Apr 2024Tracked: Solriamfetol (Sunosi)NCT06413433
Phase 2Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
Tirzepatide, Lisdexamfetamine Dimesylate, Placebo (oral), Placebo (injection)
Johns Hopkins Universityn=105United States · 1 siteStarted Sep 2025NCT06847399
Phase 2A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder
TNX-1900 (Tonix Pharmaceuticals), Placebo
Massachusetts General Hospitaln=60United States · 1 siteStarted Mar 2023NCT05664516
Phase 0Naltrexone Neuroimaging in Teens With Eating Disorders
Naltrexone, Placebo
Children's Mercy Hospital Kansas Cityn=60United States · 1 siteStarted Sep 2022NCT05509257

How many drugs are in development for binge eating disorder?: 1 compound from 1 company is in active clinical development for binge eating disorder, including 1 at Phase 3 or beyond.
Which binge eating disorder drugs are in Phase 3?: Phase 3 (or later) programs for binge eating disorder include Solriamfetol (Sunosi).
What are the next binge eating disorder trial readouts?: Upcoming catalysts include Solriamfetol (Sunosi) (2H 2026).
How many clinical trials are recruiting for binge eating disorder?: 5 drug-interventional binge eating disorder trials are currently recruiting participants, out of 62 registered interventional trials.